Velaglucerase alfa

Velaglucerase alfa (trade name VPRIV), manufactured by Shire plc is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme.[1] It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26, 2010.[2]

Velaglucerase alfa
Clinical data
License data
Routes of
administration		Infusion
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityN/A
Elimination half-lifePlasma: 5–12 minutes (absorbed by macrophages)
Identifiers
ChemSpider
  • none
UNII
ChEMBL
Chemical and physical data
FormulaC2532H3850N672O711S16
Molar mass55.5 kg/mol (unglycosylated) g·mol−1
 NY (what is this?)  (verify)

Competitive products

Imiglucerase is Genzyme's version of recombinant glucocerebrosidase. It is marketed globally under the trade name of Cerezyme.

In addition, Protalix and Pfizer have received approval for marketing taliglucerase alpha in Israel, Brazil, Canada and the U.S. The companies are expected also to file for marketing authorization in Europe and elsewhere around the world.

References
  1. University of Birmingham: Velaglucerase alfa for type 1 Gaucher’s disease
  2. Medical News Today: Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease, 27 February 2010


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.